10x Genomics, Inc. - TXG STOCK NEWS

Fanatics has appointed Lydia Jett and Jonathan Mildenhall to its board of directors, bringing extensive experience from fintech, e-commerce, and marketing sectors. Jett, from SoftBank, played a crucial role in Fanatics' growth since their initial $1 billion investment in 2017. Mildenhall, former CMO of Airbnb, is noted for transforming brand strategies. Both directors will guide Fanatics in expanding its diverse portfolio, which includes licensed merchandise, digital collectibles, and online sports betting. Additionally, Fanatics released its first ESG report, highlighting its commitment to sustainability and social responsibility.

10x Genomics, Inc. (Nasdaq: TXG) reported Q1 2022 revenue of $114.5 million, an 8% increase year-over-year. The growth stemmed from higher consumables and instrument sales, particularly the Chromium X Series. However, gross margin decreased to 78% from 84%, attributed to product mix changes and rising costs. Operating expenses rose 32% to $130.8 million, leading to an operating loss of $41.7 million and a net loss of $42.4 million. The company maintains its revenue guidance of $600 million to $630 million for 2022, projecting 22% to 28% growth.

On April 26, 2022, 10x Genomics (Nasdaq: TXG) announced their participation in the BofA Securities 2022 Healthcare Conference in Las Vegas. The management team will engage in a fireside chat on May 10 at 8:40 a.m. PT. A live and archived webcast of this presentation will be accessible through the company's website. 10x Genomics specializes in innovative life science technology aimed at understanding biological systems, with their products widely used by leading research institutions and pharmaceutical companies globally.

10x Genomics (TXG) announced the launch of the Fixed RNA Profiling Kit and Nuclei Isolation Kit on April 14, 2022. These products enhance sample preparation workflows for single cell analysis, targeting the challenges in handling fragile human tissues and frozen samples. The Fixed RNA Profiling Kit allows researchers to store samples post-collection without cryopreservation, while the Nuclei Isolation Kit simplifies the extraction of nuclei from frozen tissue, making the process more efficient. Both kits are set to ship mid-May 2022, aiming to broaden the use of single cell analysis in research.

10x Genomics (Nasdaq: TXG) will report its financial results for Q1 2022 after market close on May 4, 2022. A conference call to discuss these results, along with business developments and future outlook, will begin at 1:30 p.m. PT / 4:30 p.m. ET. The live audio of the webcast will be accessible through the company's website and archived for 45 days. 10x Genomics focuses on life science technology advancements, with significant adoption in top global research institutions and pharmaceutical companies.

10x Genomics (Nasdaq: TXG) will participate in the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 12:50 p.m. ET. The company's management will engage in a virtual fireside chat to discuss business activities. Interested parties can access the live and archived webcast through the company's website.

Recognized for advancing human health, 10x Genomics provides integrated solutions for biological analysis, widely used by premier research institutions and pharmaceutical companies globally.

10x Genomics (Nasdaq: TXG) announced new product details at its Xperience 2022 virtual event, showcasing innovations in single cell and spatial analysis technologies. Key products include the Chromium Fixed RNA Profiling Kit for improved sample preparation, Visium CytAssist to enhance spatial analysis capabilities, and a preview of the Xenium Analyzer, targeting gene expression at subcellular resolution. The company emphasizes its commitment to advancing human health through groundbreaking technologies, with multiple product launches planned for 2022.

10x Genomics, Inc. (Nasdaq: TXG) reported strong financial results for Q4 and full year 2021, with revenues of $143.5 million for Q4 and $490.5 million for the year, reflecting increases of 28% and 64%, respectively, compared to 2020. Gross margins for Q4 were 81%, slightly down from 83% year-over-year. Significant operating losses decreased to $15.8 million in Q4 from $409.6 million a year earlier. For 2022, the company projects revenues of $600 million to $630 million, indicating 22% to 28% growth.

10x Genomics (Nasdaq: TXG) will release its fourth quarter and full year financial results for 2021 on February 16, 2022. A conference call is scheduled at 1:30 p.m. PT to discuss the results and future outlook. The company's integrated solutions for biological analysis have been widely adopted globally, with significant citations in research. 10x Genomics holds a robust patent portfolio exceeding 1,300 patents.